Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer.

× No keyword cloud information.

7 in total

1. Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.

Authors: Jiannan Liu; Shuhua Wang; Congcong Wang; Xiangshuo Kong; Ping Sun
Journal: Exp Ther Med Date: 2021-01-22 Impact factor: 2.447

Review 2. Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment.

Authors: Qiujun Guo; Jinyin Lin; Rui Liu; Yebo Gao; Shulin He; Xinyao Xu; Baojin Hua; Conghuang Li; Wei Hou; Honggang Zheng; Yanju Bao
Journal: Evid Based Complement Alternat Med Date: 2015-06-10 Impact factor: 2.629

3. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.

Authors: Marie Viala; Akiko Chiba; Simon Thezenas; Laure Delmond; Pierre-Jean Lamy; Sarah L Mott; Mary C Schroeder; Alexandra Thomas; William Jacot
Journal: BMC Cancer Date: 2018-07-30 Impact factor: 4.430

Review 4. A Potential Anti-Tumor Herb Bred in a Tropical Fruit: Insight into the Chemical Components and Pharmacological Effects of Momordicae Semen.

Authors: Xiao-Rong Xu; Chuan-Hong Luo; Bo Cao; Run-Chun Xu; Fang Wang; Xi-Chuan Wei; Ting Zhang; Li Han; Ding-Kun Zhang
Journal: Molecules Date: 2019-10-31 Impact factor: 4.411

Review 5. Recent advances in therapeutic strategies for triple-negative breast cancer.

Authors: Yun Li; Huajun Zhang; Yulia Merkher; Lin Chen; Na Liu; Sergey Leonov; Yongheng Chen
Journal: J Hematol Oncol Date: 2022-08-29 Impact factor: 23.168

6. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.

Authors: Haolong Li; Lei Liu; Haocai Chang; Zhengzhi Zou; Da Xing
Journal: Cell Death Dis Date: 2018-01-26 Impact factor: 8.469

7. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.

Authors: Yu Liu; Xuemei Ji; Nannan Kang; Junfei Zhou; Xue Liang; Jiaxin Li; Tianzhen Han; Chen Zhao; Tianwu Yang
Journal: Cell Death Dis Date: 2020-11-19 Impact factor: 8.469

7 in total